Document is current

Article History

Received: 17 July 2024

Accepted: 7 January 2025

First Online: 4 February 2025

Declarations

:

: The authors did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. Alexander JE Foss has received writing support from Boehringer Ingelheim. David Almeida is Co-Founder and Chief Medical Advisor of Citrus Therapeutics and holds equity with this company. David Almeida declares involvement with AbbVie, ACELYRIN, Alcon, Alimera Sciences, Allergan, Bausch + Lomb, Bayer, Boehringer Ingelheim, Dutch Ophthalmics, EyePoint Pharmaceuticals, Genentech, Gyroscope Therapeutics, Novartis, Opthea, Regeneron, REGENXBIO, Roche, Samsara Vision and Spherix Consulting Group. Chui Ming Gemmy Cheung declares involvement with Bayer, Boehringer Ingelheim, Iveric Bio, Novartis, Roche, Topcon, and Zeiss. Yuichiro Ogura declares consultancy for Alcon Japan, Apellis, Bayer, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd, HOYA, Iveric Bio, Kyoto Drug Discovery & Development, Novartis, Senju; research support from Bayer, Kowa, Nikon Healthcare, Novartis, Santen, Topcon, and ZEISS; and is an employee of Genentech, Inc. Eduard de Cock and Theo Empeslidis are employees of Boehringer Ingelheim.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.